Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
108.95
+0.25 (0.23%)
At close: May 12, 2025, 4:00 PM
110.01
+1.06 (0.97%)
After-hours: May 12, 2025, 7:32 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
4.01
Revenue / Employee
$701,369
Employees
75,883
Market Cap
213.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 42.90B |
NVS News
- 4 hours ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 7 hours ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 14 hours ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 16 hours ago - Novartis to keep making malaria drugs if orders dry up amid aid cuts - Reuters
- 3 days ago - Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks. - Barrons
- 7 days ago - BioNTech says Novartis executive Zapata-Gomez to become CFO - Reuters
- 12 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 12 days ago - Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga